Neuronal Pentraxin 2 Binds Complement Protein, Protects Synapses
NPTX2 binds complement C1q, disrupting signals to microglia to destroy synapses.
588 RESULTS
Sort By:
NPTX2 binds complement C1q, disrupting signals to microglia to destroy synapses.
Volunteers who practiced daily slow-breathing exercises for a month lowered Aβ42 in their blood; could this diminish the risk of AD?
The protein content of extracellular vesicles sampled from hippocampal interstitial fluid depended on age, sex, and amyloid load.
The p-tau217/tau217 ratio in the cerebrospinal fluid tightly correlated with amyloid, while p-tau205/tau205 best detected neurofibrillary tangles and neurodegeneration.
Cognitively normal older adults with high levels of the biomarker slid quickly toward dementia.
Mis-splicing events produce novel proteins that can be detected in the cerebrospinal fluid of ALS/FTD patients before their symptoms start.
Therapeutics research in the field ended on high hopes that lecanemab’s Phase 3 data would carry this anti-Aβ antibody to regulatory approval in country after country in 2023. This wave drew power from progress in biomarker research; but alas, much work remains to be done.
In some patients, the blood Aβ42/40 test fell too close to the cutoff for specialists to confidently diagnose AD. Comorbidities, drugs also complicate results. Two CSF tests are FDA-approved.
Plasma p-tau climbs as bears sleep. Post-torpor, tau reverts to normal. Does neuronal metabolic activity have to do with it?
Brain-derived forms of tau distinguished people with Alzheimer's from those with other neurodegenerative diseases.
Mirroring earlier results, a larger study finds that high levels of this tau fragment in CSF tracked with neurofibrillary tangles, but not amyloid plaques.
Antemortem plasma p-tau217 predicted the extent of amyloid plaques and neurofibrillary tangles seen postmortem.
In some patients, the blood Aβ42/40 test fell too close to the cutoff for specialists to confidently diagnose AD. Comorbidities, drugs also complicate results. Two CSF tests are FDA-approved.
The assay captures α-sheet structure. It detected AD with 99 percent accuracy, including among healthy people who later became cognitively impaired.
In two primary tauopathies, fragments containing tau’s microtubule-binding region drop in the CSF as they accumulate in the brain.